Ask a Friend to Take the Pledge

Ask your friends and loved ones to take the Colonoscopy Pledge

Now that you have pledged, tell your friends and loved ones about it. Learning that you have pledged to get a colonoscopy may help them decide to take a stand against colon cancer, too.

Fill out this form and we will send the e-mail below to your friend(s):

All fields required.

  1. Your name:
    Name must be at least 2 characters.
  2. Your e-mail:
    E-mail must be a valid address.
  3. Your friend's name:
    Your friend's name must be at least 2 characters.
  4. Your friend's e-mail:
    Your friend's e-mail must be a valid address.

All personal information will be kept confidential and will not be shared with any third parties other than Salix Pharmaceuticals and its designated partners.
View our full Privacy Policy.

Send a reminder email example
Back to top

Important Safety Information about MOVIPREP

MOVIPREP® (PEG-3350, sodium sulfate, sodium chloride, potassium chloride, sodium ascorbate and ascorbic acid for oral solution) is an osmotic laxative indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. MOVIPREP is contraindicated in patients with gastrointestinal (GI) obstruction, bowel perforation, gastric retention, ileus, toxic colitis or toxic megacolon, and patients who have had a severe hypersensitivity reaction to any of its components. MOVIPREP should be used with caution in patients at risk of or with fluid and electrolyte abnormalities, hyponatremia, arrhythmias, seizures, in patients with impaired renal function or patients taking concomitant medications that affect renal function, patients with known or suspected inflammatory bowel disease, patients with suspected GI obstruction or perforation, patients at risk for aspiration, and patients with glucose-6-phosphate dehydrogenase deficiency. Most common adverse reactions for split dosing (incidence ≥5%) are malaise, nausea, abdominal pain, vomiting, and upper abdominal pain. The most common adverse reactions for evening only dosing (incidence ≥5%) are abdominal distension, anal discomfort, thirst, nausea, abdominal pain, sleep disorder, rigors, hunger, malaise, vomiting, and dizziness. MOVIPREP contains 233 mg of phenylalanine per treatment. Advise patients to hydrate adequately before, during, and after the use of MOVIPREP.

You are encouraged to report negative side effects to the FDA. Visit www.fda.gov/safety/medwatch/ or call 1-800-FDA-1088.

Complete Prescribing Information pdf icon